MC2 Therapeutics is a privately held commercial stage pharmaceutical company committed to research in skin biology and development of novel treatment paradigms for people with autoimmune and chronic inflammatory skin conditions.
Our breakthrough discovery of a novel treatment paradigm for urea associated skin diseases sets the stage for an array of novel drug candidates, which is manifested in our MC2-25 projects for CKD-aP stages 3-5 (Ph2 ongoing) and for Lichen Sclerosus (Ph2a in Q1 2023). Both represents blockbuster potentials targeting major indications with no approved treatments.
Furthermore, our new formulation and drug delivery system - PAD Technology™ - has enabled development of our market drug Wynzora®️ Cream for treatment of plaque psoriasis. Wynzora®️ has been launched by MC2 in the US and by Almirall in EU and represents major growth potential. Global roll out is ongoing
Our breakthrough discovery of a novel treatment paradigm for urea associated skin diseases sets the stage for an array of novel drug candidates, which is manifested in our MC2-25 projects for CKD-aP stages 3-5 (Ph2 ongoing) and for Lichen Sclerosus (Ph2a in Q1 2023). Both represents blockbuster potentials targeting major indications with no approved treatments.
Furthermore, our new formulation and drug delivery system - PAD Technology™ - has enabled development of our market drug Wynzora®️ Cream for treatment of plaque psoriasis. Wynzora®️ has been launched by MC2 in the US and by Almirall in EU and represents major growth potential. Global roll out is ongoing
Company Type:
Privately Funded Company
Company Website:
Company HQ State:
Not Provided
Company HQ Country:
Denmark
Year Founded:
2010
Main Therapeutic Focus:
Dermatology
Lead Product in Development:
MC2-25 CKD-aP stages 3-5
Development Phase of Primary Product:
Phase II
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Not Provided
Speaker
